BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1065 related articles for article (PubMed ID: 7540696)

  • 1. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
    Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG
    J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
    Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
    Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
    Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
    Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
    Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
    J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
    Bohlius J; Reiser M; Schwarzer G; Engert A
    Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
    Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
    Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
    J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.